Blueprint Medicines Corporation announced that its Board of Directors has appointed Kate Haviland to succeed Jeff Albers as Chief Executive Officer (CEO), effective April 4, 2022. At that time, Mr. Albers will transition from his current role as Chairman, President and CEO to Executive Chairman of the Board of Directors and Ms. Haviland will transition from her current role as Chief Operating Officer (COO) to President and CEO. In addition, Ms. Haviland will be appointed to serve on the company's Board of Directors, effective April 4, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
114.4 USD | -5.10% | -1.37% | +23.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.98% | 7.16B | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+47.87% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Blueprint Medicines Corporation Announces Executive Changes, Effective April 4, 2022